Indian AI drug discovery firm Peptris Technologies secures $1 million in pre-seed funding led by Speciale Invest, aiming to expand research into rare diseases alongside cancer and inflammation. Meanwhile, Cipla increases its stake in GoApptiv, a digital pharma solutions provider, by $5 million, targeting improved access to medications in underserved Indian communities. Canadian insurtech Lydia AI partners in South Korea, integrating tech with Metlife Korea and Tobecon for predictive AI. Japanese startup Ubie plans to launch its AI-enabled symptom checker app for Android in the US, recognized for excellence at Google Play’s Best of 2023 Awards.
Indian AI drug discovery firm gets $1M to focus on rare diseases
Peptris Technologies from Bangalore, India has received $1 million in pre-seed funding in a round led by Speciale Invest.
In a statement, the AI-driven drug discovery company said it will use its fresh funds to expand its research scope to cover rare diseases, adding to its existing work in cancer and inflammation.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Cipla raises stake in digital pharma solutions provider GoApptiv
Indian pharmaceutical giant Cipla has increased its stake in GoApptiv by Rs 420 million ($5 million) to 22.99%.
It has further invested in the company, which develops end-to-end digital solutions for pharmaceutical firms, as part of its efforts to penetrate underserved communities across India and help enhance access to medications.
Canadian insurtech Lydia AI targets South Korea
Lydia AI, a Canada-based health insurance AI company, has recently signed technology integration partnerships in South Korea.
It has formalised its ongoing collaboration with Hecto Data; they are piloting a smart data ecosystem within insurer Metlife Korea’s 360Health application.
The Canadian insurtech has also entered into a new partnership with Tobecon to integrate its predictive AI capability into insurance software.
Ubie to launch Android version of AI symptom checker app in the US
Japanese startup Ubie is preparing to launch the Android version of its AI-enabled symptom checker app in the United States.
The mobile symptom checker, whose AI capability was recently recognised at Google Play’s Best of 2023 Awards, supports users in identifying their symptoms and connects them with the right healthcare provider. It is now used over 100 million times since 2020; since launching in the US last year, it has more than two million uses to date.
Source: Mobihealth News